Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

st and telephone replays of the conference call will be available approximately two hours after the completion of the call through July 4, 2007. Please dial 416-695-5800 or 800-408-3053 and enter code 3225539 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, is ongoing.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:8/27/2015)... Aug. 27, 2015   Women Grow , the fastest-growing professional ... partnering with the Cannabis World Congress & Business Exposition ... produce 15 business-focused educational sessions. CWCBExpo in LA will take ... Convention Center in Los Angeles, CA ... West Coast for the marijuana industry. The Women ...
(Date:8/27/2015)... Aug. 27, 2015   NineSigma the leading innovation ... $450M in estimated overall revenue growth and anticipates the creation ... Frontier Open Innovation Incentive (OII). In 2013, ... a grant of over $2 million to accelerate adoption of ... $10 Million and $1 Billion in revenues. To date over ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
Breaking Medicine Technology:Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... NEW YORK, Jan. 6 The Michael J. Fox ... four industry research teams for pre-clinical research on potential ... the Foundation,s Therapeutics Development Initiative. This program, ... on Parkinson,s research. TDI is part of ...
... Pharmaceuticals, a pioneer in the development of novel ... treat human disease, announced that the company has ... candidate CEQ501, an orally administered tk RNAi ... FAP (familial adenomatous polyposis). FAP is an inherited ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... two years after Hurricane Katrina slammed into the Gulf Coast, killing more than ... than $100 billion, according to a Georgia State University study. , While most ...
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading ... Education content is ICD-10 ready and available to all clients. All Krames Patient ... sets, which are more targeted and return a more comprehensive data set of ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor ... main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing ... for the highest level of clinical nursing practice. , “Our vision is to ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... quality market research promotion on the Internet. MarketPublishers.com is now authorised to ... on the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: ...
(Date:8/27/2015)... ... 2015 , ... Sunbelt® Bakery, maker of delicious granola snacks that have a ... of how protein bars should taste with the launch of its new line of ... the market today. , The new Protein Delights are individually wrapped wafer bars ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... the often seasonal allergy that affects between 10 and ... through a course of patient-adjusted dosing, according to new ... Otolaryngology Head and Neck Surgery. , During ... as allergic rhinitis, was observed in 69 patients, who ...
... Calif. - Pregnant women who are part of an Asian-white ... compared with ,couples in which both partners are white, ... Hospital and the Stanford University ,School of Medicine. , ... white ,are more likely than white women with Asian ...
... leader in the development of treatment options for the repair of ... Banks (AATB) has awarded them the prestigious AATB accreditation. This accreditation ... for screening, handling, packaging, processing, storage and distribution of tissue. ... ...
... WICHITA, Kan., Sept. 30 Tagging foods good,and ... regulations are just,single focus reactions to the childhood ... of Healthy Kids Challenge, one of the nation,s,leading ... for healthy eating and physical activity., "It,s ...
... Advisory Firm Turns to Medical Professional to Apply Rigors,of ... Us Let,Advisors Give Bad Advice About the Best Medicine ... and,surgeons are expected to base their diagnoses on what ... dealing with specific diseases and other,illnesses. Yet most financial ...
... Mass., Sept. 30 Inverness Medical,Innovations, Inc. (Amex: ... of rapid,diagnostic products for the consumer and professional ... is scheduled to,present at the Third Annual JMP ... at Le Parker Meridien in New York. His,presentation ...
Cached Medicine News:Health News:Hay fever may be best treated with self-adjusted dosing 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 3Health News: AxoGen Awarded Accreditation from American Association of Tissue Banks : Decision Affirms AxoGen's Commitment to Safety and Ethicality in the Development and Distribution of AVANCE Nerve Graft for Treatment of Peripheral Nerve Injuries 2Health News: AxoGen Awarded Accreditation from American Association of Tissue Banks : Decision Affirms AxoGen's Commitment to Safety and Ethicality in the Development and Distribution of AVANCE Nerve Graft for Treatment of Peripheral Nerve Injuries 3Health News:Tackling Obesity Through Education and FUNdraising 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 4Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 5
Blood sedimentation rate analysis...
... The Sysmex CA-7000 provides speed and ... is synonymous with Sysmex technology. ... offers throughput of up to 300 ... in multi-parameter testing. This high ...
... is our top-of-the-line device. The ... of the Qwik-Let® Elite, in ... feature. The Lan-X technology allows ... in the removal and disposal ...
... Our variable volume Finnpipette Techpette ... a high performance pipette. Advanced ... volume range, ensures quality, safety, ... of the volume range is ...
Medicine Products: